Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/28/25
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key FactsZacks Investment Research • 04/24/25
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching CloselyBenzinga • 04/21/25
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens NextThe Motley Fool • 04/18/25
Stock Market Whiplash: 3 Growth Stocks That Are No-Brainer Buys on the BounceThe Motley Fool • 04/15/25
Nasdaq Market Whiplash: 3 Stocks to Buy Hand Over Fist and Hold for DecadesThe Motley Fool • 04/12/25
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic FibrosisBusiness Wire • 04/11/25
We're About to Find Out the Answer to Warren Buffett's Pointed Question About Trump's Tariffs. Here Are 3 Stocks to Buy Depending on What That Answer Is.The Motley Fool • 04/10/25
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'Benzinga • 04/07/25
European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic FibrosisBusiness Wire • 04/07/25
Worried About Trump's New Tariffs? These 3 U.S. Companies Are Set to Weather the StormThe Motley Fool • 04/06/25
Corporate CFOs Think a Recession Is Coming. Here Are 3 Stocks to Own If They're Right.The Motley Fool • 04/04/25
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocksCNBC • 04/01/25
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline CandidatesZacks Investment Research • 04/01/25